| |
Improve clinical outcomes by creating more flexible, patient-focused protocols that enhance enrollment and boost patient engagement with IQVIA Patient Centricity in Design. Get the fact sheet. 
|
|
| By Zoey Becker Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage. |
|
|
|
By Fraiser Kansteiner Genentech will lay off 93 employees in South San Francisco starting in early October, according to a Worker Adjustment and Retraining Notification alert in California. The downsizing campaign will kick off in the fall and run through December. |
By Heather Landi After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. |
By Zoey Becker The layoffs are the latest in Bayer's massive restructuring plan that has so far impacted more than 3,000 staffers since the start of the year. |
|
Thursday, September 5, 2024 | 10am ET / 7 am PT It can be difficult to gauge a brand’s success, at pre and post-launch stages, without access to market, product, and indication-specific benchmarks that evaluate performance in several key areas. Learn how Market Research provides actionable connected intelligence to improve decision-making. Register now. 
|
|
By Gabrielle Masson Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off. |
By Kevin Dunleavy Four months after emerging from bankruptcy, Endo Pharmaceuticals is in transition again with the sudden departure of CEO Blaise Coleman. Without providing a reason, the Dublin-based company revealed Coleman’s eventful four-year tenure will end Thursday. |
By Gabrielle Masson Venture capital in biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022. |
By Angus Liu Sanofi has temporarily stopped distributing and selling its flu shots in China out of concerns of waning potency. |
By Darren Incorvaia To digest large, infrequent feasts, a python's heart works overtime by increasing oxygen use, pumping more blood and swelling in size. This rapid response requires a heart that is soft and flexible, the opposite of the stiff and fibrous heart that is characteristic of many human cardiac diseases. |
By Andrea Park Just a few months after confirming that it was in the process of developing an online service to cut out middlemen and work directly with patients to help them access vaccines, diagnostic tests and medications, Pfizer has made good on its word. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," we dive into a discussion with two founders of the Coalition for Health AI about why both local providers and the federal government must play a role in overseeing AI in healthcare. |
|
|---|
|
|
|
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now! 
|
|
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
eBook Start leveraging AI to enhance the patient experience while improving personalization, navigation and adherence with the latest free eBook by RxPx. Sponsored by: RxPx |
Whitepaper The pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. Download this playbook to discover the future of BioPharma financial analysis. Sponsored by: Visible Alpha, now a part of S&P Global Market Intelligence |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
